Direct cardiac effects of SGLT2 inhibitors
Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure patients. These inhibitors have on-target (SGLT2 inhibition in the kidney) and off-target effects that likely both contribute to th...
Main Authors: | Sha Chen, Ruben Coronel, Markus W. Hollmann, Nina C. Weber, Coert J. Zuurbier |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-03-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-022-01480-1 |
Similar Items
-
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
by: Keming Huang, et al.
Published: (2023-04-01) -
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
by: Yao Hao Teo, et al.
Published: (2021-03-01) -
Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
by: David Bobrowski, et al.
Published: (2021-11-01) -
SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis
by: Hui Lin, et al.
Published: (2021-06-01) -
SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes
by: Natalia Stepanova
Published: (2024-01-01)